Core Viewpoint - Anke Bio (300009.SZ) has entered into a strategic cooperation with its affiliate, Boshengji Pharmaceutical Technology (Suzhou) Co., Ltd., to exclusively distribute the PA3-17 injection product in Greater China after its market launch, enhancing its position in the CAR-T cell therapy sector [1][2] Group 1 - The PA3-17 injection is the world's first targeted CD7 autologous CAR-T cell therapy product approved for clinical trials, aimed at treating adult relapsed and refractory CD7-positive hematologic malignancies [1] - The product has been included in the breakthrough therapy list by the National Medical Products Administration (NMPA) and is currently in a critical Phase II clinical trial [1] - Boshengji plans to entrust Anke Bio with long-term cooperation for the sales and promotion of PA3-17 in the Greater China market, with a formal exclusive agency agreement to be signed after the product's market application submission [1] Group 2 - The exclusive agency cooperation aims to leverage the strengths of both companies, achieving synergistic development effects [2] - Through the exclusive agency model, the company can quickly introduce innovative drug products, filling existing gaps in the CAR-T cell therapy field and enriching its product matrix [2] - This partnership is expected to enhance the company's core competitiveness in the innovative drug market [2]

Core Viewpoint - Anke Bio (300009.SZ) has entered into a strategic cooperation with its affiliate, Boshengji Pharmaceutical Technology (Suzhou) Co., Ltd., to exclusively distribute the PA3-17 injection product in Greater China after its market launch, enhancing its position in the CAR-T cell therapy sector [1][2] Group 1 - The PA3-17 injection is the world's first targeted CD7 autologous CAR-T cell therapy product approved for clinical trials, aimed at treating adult relapsed and refractory CD7-positive hematologic malignancies [1] - The product has been included in the breakthrough therapy list by the National Medical Products Administration (NMPA) and is currently in a critical Phase II clinical trial [1] - Boshengji plans to entrust Anke Bio with long-term cooperation for the sales and promotion of PA3-17 in the Greater China market, with a formal exclusive agency agreement to be signed after the product's market application submission [1] Group 2 - The exclusive agency cooperation aims to leverage the strengths of both companies, achieving synergistic development effects [2] - Through the exclusive agency model, the company can quickly introduce innovative drug products, filling existing gaps in the CAR-T cell therapy field and enriching its product matrix [2] - This partnership is expected to enhance the company's core competitiveness in the innovative drug market [2]

Group 1 - The core point of the article is that Anke Bio (SZ 300009) announced a board meeting to discuss a framework agreement with Boshengji Pharmaceutical Technology (Suzhou) Co., Ltd. regarding exclusive agency and related transactions [1] - Anke Bio's revenue composition for the first half of 2025 shows that gene-engineered drugs account for 73.51%, other businesses for 16.77%, and external patches for 9.72% [1] - As of the report, Anke Bio's market capitalization is 18.7 billion yuan [1]

Core Viewpoint - The company has signed an exclusive agency framework agreement with Boshengji Company for the product CD7-CAR-T (PA3-17 injection) in the Greater China region, aiming for collaborative development and resource integration [1] Group 1 - The agreement was signed on November 11, 2025 [1] - The exclusive agency pertains to the product PA3-17 injection after its market launch [1] - The collaboration is intended to leverage the strengths of both parties for synergistic growth [1]

Core Viewpoint - The company announced a strategic partnership with Boshengji to exclusively distribute the PA3-17 injection product in Greater China, enhancing its product portfolio and competitive edge in the innovative drug market [1] Group 1: Strategic Partnership - The company has signed a framework agreement for exclusive agency rights regarding the PA3-17 injection product in Greater China, which includes mainland China and Hong Kong, Macau, and Taiwan [1] - This partnership is aimed at integrating resources from both companies to enrich the product matrix [1] - The agreement has been approved by the company's board of directors and does not require shareholder approval [1] Group 2: Product Information - PA3-17 injection is the world's first CAR-T cell therapy product targeting CD7, developed by Boshengji [1] - The initial indication for PA3-17 is for the treatment of adult relapsed and refractory CD7-positive hematologic malignancies [1] - The agreement does not specify any financial details and is not expected to have a significant impact on the company's current operating performance [1]

一、以 3 票赞成，0 票反对，0 票弃权审议通过了《关于向博生吉医药科技 （苏州）有限公司增资暨关联交易的议案》 为夯实公司创新药领域的战略布局，强化公司核心竞争力，同意公司拟以自 有资金 3,000 万元人民币对博生吉医药科技（苏州）有限公司（以下简称"博生 吉公司"）进行增资，本次增资完成后，公司持有博生吉公司 21.4121%的股权。 根据《深圳证券交易所创业板股票上市规则》规定，本次交易构成关联交易。具 体内容详见同日披露于中国证监会指定创业板信息披露网站巨潮资讯网 （www.cninfo.com.cn）的相关公告。 证券代码：300009 证券简称：安科生物 公告编号：2025-060 安徽安科生物工程（集团）股份有限公司 关于第八届监事会第二十一次会议决议的公告 本公司及监事会全体成员保证公告内容真实、准确和完整，没有虚假记载、 误导性陈述或者重大遗漏。 安徽安科生物工程（集团）股份有限公司（以下简称"公司"）第八届监事 会第二十一次会议于 2025 年 11 月 5 日以书面形式发出会议通知，2025 年 11 月 11 日上午 11:00 以现场及通讯会议的方式召开。应参会 3 人，实际参会 ...

证券代码：300009 证券简称：安科生物 公告编号：2025-058 安徽安科生物工程（集团）股份有限公司 关于向博生吉医药科技（苏州）有限公司增资暨关联交易的公告 本公司及董事会全体成员保证公告内容真实、准确和完整，没有虚假记载、误导性 陈述或者重大遗漏。 一、关联交易概述 为夯实公司在创新药领域的战略布局，强化公司核心竞争力，安徽安科生物工程（集 团）股份有限公司（以下简称"公司"）拟以自有资金3,000万元人民币对参股公司博生 吉医药科技（苏州）有限公司（以下简称"博生吉公司"）进行增资，认购博生吉公司 新增注册资本11.9062万元。本次增资完成后，公司持有博生吉公司21.4121%的股权。 鉴于公司与博生吉公司存在关联关系，根据《深圳证券交易所创业板股票上市规则》 规定，本次交易构成关联交易，但不构成《上市公司重大资产重组管理办法》规定的重 大资产重组。本次关联交易事项已经独立董事专门会议及第八届董事会战略与投资委员 会事前审议通过，本事项已经全体独立董事过半数同意，并经公司于2025年11月11日召 开的第八届董事会第二十三次会议审议通过，无需提交公司股东大会审议。 二、标的公司（关联方）基本情 ...

证券代码：300009 证券简称：安科生物 公告编号：2025-057 安徽安科生物工程（集团）股份有限公司 关于签署 PA3-17 注射液产品独家代理框架协议暨关联交易的公告 本公司及董事会全体成员保证公告内容真实、准确和完整，没有虚假记载、误 导性陈述或者重大遗漏。 特别提示： 1、本次事项构成关联交易，根据《深圳证券交易所创业板股票上市规则》《公 司章程》等规定，该事项已经公司第八届董事会第二十三次会议审议通过，无需提 交公司股东大会审议。 2、本协议不涉及具体金额，对公司当期经营业绩不会产生重大影响。 3、本协议为框架性协议，后续具体合作内容将以产品提交上市申请后签订的 正式协议为准。本次独家代理产品的上市时间存在不确定性，本次协议的履行及其 后续协议的履行存在一定不确定性，敬请广大投资者谨慎决策，注意投资风险。公 司将根据合作进展及时履行信息披露义务。 为推动参股公司博生吉医药科技（苏州）有限公司（以下简称"博生吉公司"） 旗下 PA3-17 注射液产品的销售与推广，安徽安科生物工程（集团）股份有限公司 （以下简称"公司"）与博生吉公司达成战略合作，于 2025 年 11 月 11 日签署《关 于 ...

证券代码：300009 证券简称：安科生物 公告编号：2025-059 为夯实公司创新药领域的战略布局，强化公司核心竞争力，同意公司拟以自 有资金 3,000 万元人民币对博生吉医药科技（苏州）有限公司（以下简称"博生 吉公司"）进行增资，认购博生吉公司新增注册资本 11.9062 万元，本次增资完 成后，公司持有博生吉公司 21.4121%的股权。根据《深圳证券交易所创业板股 票上市规则》规定，本次交易构成关联交易。具体内容详见同日披露于中国证监 会指定创业板信息披露网站巨潮资讯网（www.cninfo.com.cn）的相关公告。 本议案已经公司第八届董事会独立董事专门会议 2025 年第二次会议及第八 届董事会战略与投资委员会 2025 年第一次会议事前审议通过，一致同意将本议 案提交公司董事会审议。 本议案以12票同意、0票反对、0 票弃权获得通过。 2、审议通过《关于与博生吉医药科技（苏州）有限公司签署<产品独家代 安徽安科生物工程（集团）股份有限公司 关于第八届董事会第二十三次会议决议的公告 本公司及董事会全体成员保证公告内容真实、准确和完整，没有虚假记载、 误导性陈述或者重大遗漏。 安徽安科生物工 ...

Core Viewpoint - The biopharmaceutical sector experienced a decline of 0.37% on November 7, with He Yuan Bio leading the drop. The Shanghai Composite Index closed at 3997.56, down 0.25%, while the Shenzhen Component Index closed at 13404.06, down 0.36% [1]. Group 1: Stock Performance - Wan Ze Co. (000534) saw a significant increase in stock price, closing at 22.51 with an 8.80% rise and a trading volume of 754,200 shares, amounting to 1.681 billion yuan [1]. - Tibet Pharmaceutical (600211) closed at 46.05, up 2.74%, with a trading volume of 80,600 shares, totaling 371 million yuan [1]. - Anke Bio (300009) increased by 2.25%, closing at 10.93 with a trading volume of 442,300 shares, amounting to 482 million yuan [1]. - The overall biopharmaceutical sector saw a net outflow of 678 million yuan from institutional investors, while retail investors had a net inflow of 304 million yuan [2][3]. Group 2: Capital Flow - The main capital inflow was observed in Tibet Pharmaceutical, with a net inflow of 26.13 million yuan from institutional investors, while retail investors had a net outflow of 36.64 million yuan [3]. - Anke Bio also experienced a net inflow of 23.91 million yuan from institutional investors, with retail investors seeing a net outflow of 13.09 million yuan [3]. - The overall trend indicates a mixed sentiment in the biopharmaceutical sector, with institutional investors pulling back while retail investors showed some interest [2][3].